Proceedings from the National Cancer Institute%26apos;s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part II. Autologous Transplantation-Novel Agents and Immunomodulatory Strategies

作者：Avigan David; Hari Parameswaran; Battiwalla Minoo; Bishop Michael R; Giralt Sergio A; Hardy Nancy M^*; Kroeger Nicolaus; Wayne Alan S; Hsu Katharine C

来源：Biology of Blood and Marrow Transplantation, 2013, 19(12): 1661-1669.

DOI：10.1016/j.bbmt.2013.08.011

• Relapse
• Hematopoietic stem cell transplantation
• Autologous
• Allogeneic
• Multiple myeloma

In the National Cancer Institute%26apos;s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on Autologous Transplantation addressed the role of novel agents and immunomodulatory strategies in management of relapse after autologous hematopoietic stem cell transplantation (AHSCT). Concepts were illustrated through in-depth discussion of multiple myeloma, with broader discussion of areas relevant for relapse of other malignancies as well as in the setting of allogeneic transplantation. Dr. Hari provided an overview of the epidemiology of relapse after AHSCT in multiple myeloma, addressing clinical patterns, management implications, and treatment options at relapse, highlighting the implications of novel therapeutic agents in initial, maintenance, and relapse treatment. Dr. Avigan discussed current concepts in tumor vaccine design, including whole cell and antigen-specific strategies, use of an AHSCT platform to reverse tumor-associated immunosuppression and tolerance, and combining vaccines with immunomodulatory agents to promote establishment of durable antitumor immunity. Dr. Hsu reviewed the immunogenetics of natural killer (NK) cells and general NK biology, the clinical importance of autologous NK activity (eg, lymphoma and neuroblastoma), the impact of existing therapies on promotion of NK cell activity (eg, immunomodulatory drugs, monoclonal antibodies), and strategies for enhancing autologous and allogeneic NK cell effects through NK cell gene profiling. Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.

• 出版日期2013-12